BlinkLab Raises $17.5M to Complete FDA Trial for Autism Diagnostic Platform
BlinkLab Limited has successfully completed an oversubscribed capital raise, securing $17.5 million (before costs) to advance its autism diagnostic platform towards FDA approval and expand into the larger ADHD market. The placement drew domestic and international institutional investors, with the company’s Board and management committing $200,000, demonstrating insider confidence at this pivotal regulatory stage.
BlinkLab raises $17.5 million to advance autism diagnostic towards FDA approval
The placement was priced at $0.65 per share, representing a 17.2% discount to the last traded price on 13 April 2026 and a 15.3% discount to the 15-day volume-weighted average price (VWAP). The company will issue 26,923,077 new ordinary shares to sophisticated and institutional investors.
Key raise metrics:
- $17.5 million raised before costs
- $0.65 per share issue price
- 17.2% discount to last traded price
- 15.3% discount to 15-day VWAP
- 26,923,077 new shares to be issued
- $200,000 committed by Board and management
The oversubscribed nature of the placement signals institutional validation of BlinkLab’s clinical progress and commercial pathway. Insider participation at the offer price aligns management interests with shareholders as the company approaches its FDA 510(k) registrational trial completion for autism diagnosis using the BlinkLab Dx1 platform.
When big ASX news breaks, our subscribers know first
Where the funds will be deployed
BlinkLab’s capital allocation strategy addresses both near-term FDA milestones and longer-term platform diversification across multiple neurodevelopmental conditions. The proceeds will fund a dual-track approach: completing the autism regulatory pathway whilst initiating ADHD expansion.
Programme allocation includes:
- Completion of the ongoing FDA 510(k) registrational trial for autism diagnosis using BlinkLab Dx1
- CE marking and MDR approval processes for European market access
- Launch of U.S. clinical programme for ADHD using BlinkLab Dx2 platform
- Initiation of FDA 510(k) registrational trial for ADHD detection
- Working capital, platform development, and patent portfolio extension
The European regulatory strategy, encompassing CE marking and compliance with EU Medical Device Regulation (MDR) requirements, positions the BlinkLab Dx1 platform for access across major international markets beyond the United States.
| Programme | Indication | Regulatory Pathway |
|---|---|---|
| BlinkLab Dx1 | Autism | FDA 510(k) registrational trial ongoing; CE/MDR approval process underway |
| BlinkLab Dx2 | ADHD | U.S. clinical studies launching; FDA 510(k) trial initiation planned |
ADHD represents a substantially larger patient population than autism, expanding BlinkLab’s total addressable market whilst leveraging existing platform infrastructure with minimal incremental development cost.
How smartphone-based neurological diagnostics work
BlinkLab’s technology platform uses smartphone applications to capture digital biomarkers from a child’s interaction with the device. These biomarkers, generated through the app interface, are analysed using artificial intelligence and machine learning algorithms to support clinical diagnosis of neurodevelopmental conditions.
The platform can screen children as young as 18 months old, compared to typical autism diagnosis around five years of age. Earlier identification during critical developmental windows allows for intervention when neuroplasticity is at its peak, potentially improving long-term patient outcomes.
Traditional diagnosis versus BlinkLab approach:
- Traditional: Diagnosis around five years old, long wait times, subjective assessments, specialist-dependent
- BlinkLab: Screening from 18 months, smartphone-accessible, objective AI-powered analysis, scalable deployment
Objective, scalable diagnostics address the current bottleneck of subjective assessments and specialist shortages. Long waiting times and variability in access to specialists create significant burden on both patients and healthcare systems, an unmet need BlinkLab’s platform is designed to address.
Clinical validation underpinning the FDA pathway
In October 2025, BlinkLab reported pilot study results for its Dx1 platform that confirmed high diagnostic accuracy and exceeded FDA-agreed performance thresholds. The positive pilot data de-risks the registrational pathway and supports confidence in timeline achievement for regulatory submission.
The company is now focused on delivering robust real-world evidence through its registrational programme, building on validated clinical data to support FDA 510(k) clearance as an aid in the diagnostic process for autism. This represents a key inflection point underpinning BlinkLab’s pathway to becoming a clinically validated, scalable diagnostic platform.
ADHD expansion creates larger market opportunity
The ADHD programme leverages the same smartphone-based platform and AI-driven infrastructure as BlinkLab Dx1, creating a complementary opportunity with minimal incremental development cost. The Dx2 platform uses the exact same smartphone technology, app, and online portal, but analyses slightly different digital biomarkers to evaluate brain function and detect possible indicators of ADHD.
ADHD represents a significantly larger patient population than autism, multiplying BlinkLab’s commercial opportunity. Platform optionality beyond autism creates competitive moat and operational leverage, positioning the company to address a broader spectrum of neurodevelopmental conditions.
A portion of the placement proceeds will be allocated to advancing the U.S.-focused ADHD programme, including initiation of clinical studies to expand BlinkLab’s platform into this complementary market opportunity.
Management perspective on the milestone
Co-founder, Managing Director & CEO Dr Henk-Jan Boele emphasised the clinical need and BlinkLab’s positioning to address diagnostic challenges in neurodevelopmental conditions.
Dr Henk-Jan Boele, Co-founder, Managing Director & CEO
“As a medical doctor, I have seen first-hand the challenges families face in navigating the diagnostic journey for autism and other neurodevelopmental conditions. Long waiting times, subjective assessments, and variability in access to specialists create a significant burden on both patients and healthcare systems.”
Dr Boele highlighted that the funding positions BlinkLab to complete its pivotal U.S. study and progress towards FDA approval, whilst also advancing the European regulatory strategy and expanding into ADHD.
Non-Executive Chairman Brian Leedman commented on the quality of institutional investors participating in the placement and the strategic importance of the U.S. market.
Brian Leedman, Non-Executive Chairman
“We are very pleased with the strong support received for this placement, particularly from high-quality institutional investors who share our long-term vision. At this stage of the Company’s development, it is critical to build a register that is aligned with our strategy, especially as we prepare to enter the United States, the largest and most important healthcare market globally.”
Placement structure and next steps
The new shares will be issued using BlinkLab’s existing placement capacity under ASX Listing Rules. A total of 14,656,983 shares will be issued under the company’s 15% placement capacity (Listing Rule 7.1), with 12,000,000 shares issued within the additional 10% placement capacity (Listing Rule 7.1A).
Key placement mechanics and dates:
- 14,656,983 shares under Listing Rule 7.1
- 12,000,000 shares under Listing Rule 7.1A
- 266,094 shares to directors (subject to shareholder approval)
- 41,598 shares to management
- Settlement date: 23 April 2026
- General meeting for director shares: mid-June 2026
The new shares utilising the combined 7.1 and 7.1A placement capacity are expected to settle on Thursday 23 April 2026. The proposed issue of shares to directors requires shareholder approval at a general meeting convened for mid-June 2026.
Morgans Corporate Limited, Westar Capital Ltd, and Alpine Capital Pty Ltd acted as Joint Lead Managers (JLM) to the placement. The JLM will receive 7% of gross funds raised, with fees split equally between the three managers. The JLM will also receive one option for every five shares issued under the placement, with an exercise price of $0.975 per option and expiry date of 30 June 2028. The issue of options to the JLM is subject to shareholder approval at the mid-June general meeting.
The options structure aligns JLM incentives with share price appreciation, requiring the share price to reach $0.975 (a 50% premium to the placement price) before the options become in-the-money.
The next major ASX story will hit our subscribers first
Investment thesis and catalysts ahead
This capital raise positions BlinkLab for value inflection across multiple near-term catalysts spanning two programmes and two major regulatory jurisdictions. The company sits at the intersection of digital health, AI diagnostics, and paediatric neurodevelopment megatrends.
Key upcoming milestones and catalysts:
- Completion of FDA 510(k) registrational trial for autism (BlinkLab Dx1)
- FDA 510(k) submission and clearance decision for autism diagnostic aid
- CE marking and MDR approval for European market access
- Initiation of U.S. clinical studies for ADHD (BlinkLab Dx2)
- Commencement of FDA 510(k) registrational trial for ADHD
The sector benefits from powerful tailwinds including growing acceptance of AI-powered diagnostics, increasing regulatory openness to digital biomarkers, and urgent unmet need in neurodevelopmental screening. Autism and related conditions remain significantly underdiagnosed, with long waiting times creating clear clinical need for objective, accessible, and scalable diagnostic solutions.
BlinkLab’s dual-track strategy significantly enhances the company’s ability to capture early mover advantage in markets increasingly demanding technology-driven diagnostic solutions. The ability to leverage a single platform across multiple neurodevelopmental conditions creates competitive moat and operational leverage as the company transitions from clinical validation into commercial readiness.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements hit the ASX.